Intratympanic treatment of hearing loss with novel and traditional agents.
As knowledge of the cellular and molecular pathophysiology behind otopathologies expands, the possibility exists of preventing sensorineural hearing loss and perhaps reversing the loss. Cellular and molecular mechanisms seem to be similar in hearing loss secondary to aging, drug ototoxicity, noise, or other mechanisms. A final common pathway may hinge upon apoptosis. It is likely that anti-apoptotic factors will increasingly be realized as an important intervention strategy for sensorineural hearing loss. Furthermore, it is also possible that mounting a staged attack at the various regions in the pathway leading to cellular damage using a combination of several protective substances such as steroids, antioxidants, neurotrophic factors, anti-apoptotic compounds, and mitochondrial enhancers may prevent hearing loss and even reverse it in some situations. This article has presented some of the molecular and cellular mechanisms for hearing loss and potential ways of treating them. In theory, the delivery of these medications to the inner ear transtympanically would decrease systemic side effects and be more target specific. Because most of the studies conducted to date have been animal studies, randomized, double-blind, placebo-controlled clinical trials would be necessary before the use of these therapies becomes common practice.
Seidman
Michael D
MD
Department of Otolaryngology-Head and Neck Surgery, Henry Ford Medical Center, 2799 West Grand Boulevard, Detroit, MI 48202, USA. mseidma1@hfhs.org
Vivek
Prashant
P
D000287:Administration, Topical; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D015853:Cysteine Proteinase Inhibitors / Q000008:administration & dosage; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage; D015316:Genetic Therapy; D005938:Glucocorticoids / Q000008:administration & dosage; D006023:Glycoproteins / Q000008:administration & dosage; D034381:Hearing Loss / Q000188:drug therapy*; D006801:Humans; D009414:Nerve Growth Factors / Q000008:administration & dosage; D010713:Phosphatidylcholines / Q000008:administration & dosage; D012405:Round Window, Ear / Q000378:metabolism; D014432:Tympanic Membrane
D000975:Antioxidants; D015853:Cysteine Proteinase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D005938:Glucocorticoids; D006023:Glycoproteins; D009414:Nerve Growth Factors; D010713:Phosphatidylcholines; C039304:calpain inhibitors